Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 76

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 76
---
 proceeds from this offering. See “Risk Factors” for a discussion of certain risks that may affect our intended use of the net proceeds from this offering.

<div align='center'>**42

Market Price of our Common Stock and Related Stockholder Matters**</div>

#### Market Information
Our common stock is listed on The Nasdaq Stock Market under the symbol “PTPI.” A description of the common stock that we are issuing in this offering is set forth under the heading “Description of Securities We Are Offering” beginning on page 56 of this prospectus. We do not intend to apply for the listing of the Pre-Funded Warrants or Series Warrants that are part of this offering on any national securities exchange.

The last reported sale price for our common stock on February 18, 2025, was $0.1363 per share.

#### Holders
As of February 13, 2025, we had 299 record holders of our common stock, and 8 record holders of our Series A Preferred Stock. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of common stock whose shares are held in the names of various security brokers, dealers, and registered clearing agencies. The transfer agent and registrar for our common stock is Pacific Stock Transfer Co. The transfer agent’s address is 725 Via Austi Parkway, Suite 300, Las Vegas, Nevada 89119.

#### Dividends
We have never declared or paid any cash dividends on our common stock. So long as any shares of Series A Preferred Stock are outstanding, as they are at this time, we are not able to declare or pay any cash dividend or distribution on any of our capital stock (other than as required by the Certificate of Designations) without the prior written consent of the Required Holders (as defined in the Certificate of Designations). We currently anticipate that we will retain future earnings to fund development and growth of our business, and we do not anticipate paying cash dividends on our common stock in the foreseeable future. The decision to pay dividends is at the discretion of our Board and depends upon our ability to obtain a waiver of the restriction on paying dividends contained in our credit facility, and on our financial condition, results of operations, capital requirements, and other factors that our Board deems relevant.

<div align='center'>43</div>

Capitalization The following table sets forth our capitalization as of September 30, 2024:

| ● | on an actual basis; |

| ● |